TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21649623

Group type: EXPERIMENTAL
Intervention: Geriatric Risk Assessment MedGuide (GRAM) reports and automated monitoring plans for falls and delirium
Number of subjects: 1711
Study: 20077901

Group type: EXPERIMENTAL
Intervention: Oral health education programme and fluoride toothpaste use under parental supervision
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control group with no intervention
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Oral health education programme
Number of subjects: 400
Study: 16773005

Group type: EXPERIMENTAL
Intervention: Intraperitoneal CO2 insufflation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Abdominal wall lift
Number of subjects: 30
Study: 15544879

Group type: EXPERIMENTAL
Intervention: Amoxycillin for 5 days (long-term group)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo (short-term group)
Number of subjects: 34
Study: 12536735

Group type: EXPERIMENTAL
Intervention: Phosphocreatine (neoton) group (group CP) - 4.0 g neoton intravenously 2 days before operation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (group C) - 5% G. S instead of neoton
Number of subjects: 20
Study: 9434695

Group type: EXPERIMENTAL
Intervention: Cold blood cardioplegia (4:1 dilution, blood/Plegisol, potassium chloride 15 mEq/L; n = 62)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Cold crystalloid cardioplegia (Plegisol; n = 76)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 138
Study: 8311290

Group type: EXPERIMENTAL
Intervention: Propofol-midazolam-alfentanil
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Midazolam-alfentanil
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Midazolam-propofol
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Propofol-alfentanil
Number of subjects: 130
Study: 2455425

Group type: EXPERIMENTAL
Intervention: Single oral dose of 25 mg methotrexate
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Single intramuscular injection of 25 mg methotrexate
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Long-term maintenance methotrexate therapy
Number of subjects: 23
Study: 31839501

Group type: EXPERIMENTAL
Intervention: Doxepin cream
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 27
Study: 30833170

Group type: EXPERIMENTAL
Intervention: Semaglutide 1·0 mg
Number of subjects: 302

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study: 29096777

Group type: EXPERIMENTAL
Intervention: PedPRM (2 mg escalated to 5 mg)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study: 26296794

Group type: EXPERIMENTAL
Intervention: 250 μg roflumilast
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: 500 μg roflumilast
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: 1000 μg roflumilast
Number of subjects: 197

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study: 23163793

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MD)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Non-Mediterranean diet (non-MD)
Number of subjects: 22
Study: 21777019

Group type: EXPERIMENTAL
Intervention: PAS(LTP) - 200 repetitions of TMS pulses paired with median nerve electrical stimulation at ISI equal to individual latencies of evoked response of somatosensory cortex (N(20)).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PAS(LTD) - 200 repetitions of TMS pulses paired with median nerve electrical stimulation at ISI of N(20) shortened for 5 msec.
Number of subjects: 0
Study: 19563187

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation and oral administration of placebo
Number of subjects: 250

Group type: COMPARATOR
Intervention: Oral administration of Mosapride citrate dispersible tablets, Domperidone, and Omeprazole with placebo treatment of transcutaneous electrical acupoint stimulation
Number of subjects: 250
Study: 16719611

Group type: EXPERIMENTAL
Intervention: Higher trait anxiety
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Greater asthma severity
Number of subjects: 86
Study: 15079110

Group type: EXPERIMENTAL
Intervention: Primary percutaneous transluminal coronary angioplasty
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thrombolysis
Number of subjects: 0
Study: 11240871

Group type: EXPERIMENTAL
Intervention: Atropine 0.01 mg.kg‐1
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Metoclopramide 0.2 mg.kg‐1
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Atropine 0.01 mg.kg‐1 plus Metoclopramide 0.2 mg.kg‐1
Number of subjects: 45
Study: 9372483

Group type: EXPERIMENTAL
Intervention: Resistance exercise (REX)
Number of subjects: 16

Group type: COMPARATOR
Intervention: No exercise (NOE)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Maximal plantar flexor EMG
Number of subjects: 16
Study: 8514073

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 122

Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 122
Study: 3797469

Group type: EXPERIMENTAL
Intervention: Lithium levels 0.46‐0.60 mEq/l (group B)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Lithium levels 0.61‐0.75 mEq/l (group C)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Lithium levels 0.76‐0.90 mEq/l (group D)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Lithium levels 0.30‐0.45 mEq/l (group A)
Number of subjects: 4

Group type: COMPARATOR
Intervention: All groups compared to group A
Number of subjects: 4
Study: 31751547

Group type: EXPERIMENTAL
Intervention: Current epilepsy treatments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Precision medicine for improved seizure control and reduced toxicity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Advances from genomic sequencing techniques
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Identification of potential new therapeutic targets
Number of subjects: 0
Study: 29681046

Group type: EXPERIMENTAL
Intervention: Colchicine 1 g/day orally for two months
Number of subjects: 84

Group type: COMPARATOR
Intervention: Non-receiving (control)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Colchicine treatment
Number of subjects: 84
Study: 27895846

Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 2767

Group type: EXPERIMENTAL
Intervention: Cefdinir
Number of subjects: 2767

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2767
Study: 24115337

Group type: EXPERIMENTAL
Intervention: Subjects with T1D >2 years
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Subjects with T1D <1 year
Number of subjects: 92

Group type: COMPARATOR
Intervention: Historical non-diabetic controls
Number of subjects: 92
Study: 23696104

Group type: EXPERIMENTAL
Intervention: 4 weeks of integrative body-mind training (IBMT)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Relaxation control
Number of subjects: 34
Study: 22050795

Group type: EXPERIMENTAL
Intervention: Follicular phase (propofol anesthesia at 1.5-2.0 μg/mL)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Mid-late luteal phase (propofol anesthesia at 1.5-2.0 μg/mL)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Comparison of ΔP(CRIT) between phases
Number of subjects: 12

Group type: COMPARATOR
Intervention: R(US) measurements
Number of subjects: 12
Study: 18838589

Group type: EXPERIMENTAL
Intervention: Ritonavir plus raltegravir (400 mg raltegravir; 100 mg ritonavir every 12 h for 16 days with 400 mg raltegravir on day 14)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Efavirenz plus raltegravir (400 mg raltegravir; 600 mg efavirenz once daily for 14 days with 400 mg raltegravir on day 12)
Number of subjects: 0
Study: 17153880

Group type: EXPERIMENTAL
Intervention: 75000 SQ-T units
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 150000 SQ-T units
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 300000 SQ-T units
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 500000 SQ-T units
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 12409281

Group type: EXPERIMENTAL
Intervention: High-fat diet (HF)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Low-fat diet (LF)
Number of subjects: 12
Study: 11022421

Group type: EXPERIMENTAL
Intervention: Ramipril (R)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Enalapril (E)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Caposide-50 (C-50)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Cintome (Ci)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Acetene (A)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Cozaar (Co)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Melatonin
Number of subjects: 124
Study: 8865280

Group type: EXPERIMENTAL
Intervention: Human milk
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: SMA Super Preemie formula
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Similac, Special Care formula
Number of subjects: 28
Study: 1800454

Group type: COMPARATOR
Intervention: Double blind placebo controlled clinical trial
Number of subjects: 81
Study: 6213380

Group type: EXPERIMENTAL
Intervention: Topical benzoyl peroxide 5 percent
Number of subjects: 39

Group type: COMPARATOR
Intervention: Topical benzoyl peroxide 5 percent in 8 percent urea
Number of subjects: 39
Study: 31910989

Group type: EXPERIMENTAL
Intervention: Teaching operations
Number of subjects: 4560

Group type: EXPERIMENTAL
Intervention: Junior surgeons
Number of subjects: 4560

Group type: EXPERIMENTAL
Intervention: Surgical experience
Number of subjects: 4560

Group type: EXPERIMENTAL
Intervention: Procedures of shorter and medium duration
Number of subjects: 4560
Study: 30298625

Group type: EXPERIMENTAL
Intervention: 12 weeks of supervised aerobic exercise training (EX)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 12
Study: 27795558

Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO)
Number of subjects: 1583

Group type: EXPERIMENTAL
Intervention: 6 mg/m2 Gemtuzumab ozogamicin (GO)
Number of subjects: 1583

Group type: COMPARATOR
Intervention: No Gemtuzumab ozogamicin (GO)
Number of subjects: 1583
Study: 25792557

Group type: EXPERIMENTAL
Intervention: Home aerobic exercise training (EX) consisting of 8 weeks of home walking for 1 hour/day, 5 days/week at 60% to 80% of heart rate reserve, followed by 16 weeks of maintenance home walking for 150 min/week.
Number of subjects: 160

Group type: COMPARATOR
Intervention: Usual care (UC) with no exercise directives, monitored by monthly telephone contact.
Number of subjects: 160
Study: 24461523

Group type: EXPERIMENTAL
Intervention: P. niruri infusion (5 g/750 mL)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Water (control group)
Number of subjects: 5
Study: 22935645

Group type: EXPERIMENTAL
Intervention: Biased information pamphlet
Number of subjects: 216

Group type: COMPARATOR
Intervention: Neutral information pamphlet
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Both groups (biased and neutral)
Number of subjects: 216
Study: 20095496

Group type: EXPERIMENTAL
Intervention: W‐F168‐B dialyzer reprocessing machine
Number of subjects: 0

Group type: COMPARATOR
Intervention: RENATRON II dialyzer reprocessing machine
Number of subjects: 0
Study: 17824581

Group type: EXPERIMENTAL
Intervention: Combination therapy with clindamycin 1%-BPO 5% topical gel plus tretinoin microsphere gel 0.04%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapy with clindamycin 1%-BPO 5% topical gel plus tretinoin microsphere gel 0.1%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapy with clindamycin 1%-BPO 5% topical gel plus adapalene gel 0.1%
Number of subjects: 0
Study: 15145332

Group type: EXPERIMENTAL
Intervention: Acarbose (Aca)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Voglibose (Vog)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Acarbose (Aca) and Voglibose (Vog)
Number of subjects: 20
Study: 11210872

Group type: EXPERIMENTAL
Intervention: Fibrin sealant
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no fibrin sealant)
Number of subjects: 20
Study: 9780616

Group type: EXPERIMENTAL
Intervention: Lacidipine (4 mg/die)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Idroclorotiazide + amiloride (50 mg every other day)
Number of subjects: 19
Study: 8155437

Group type: EXPERIMENTAL
Intervention: Space blanket (not less than 60% of body surface area)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Standard surgical draping
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Space blanket
Number of subjects: 68
Study: 3283632

Group type: EXPERIMENTAL
Intervention: nonselective beta‐blocker (timolol maleate 0.5%)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: cardioselective beta‐1‐blocking agent (betaxolol‐HCl 0.5%)
Number of subjects: 60

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study: 31112706

Group type: EXPERIMENTAL
Intervention: Aloe polysaccharide (APS) 600 mg/day
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Propolis 600 mg/day
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Mixture of APS (420 mg/day) and propolis (180 mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (smokers without supplementation)
Number of subjects: 40
Study: 28951766

Group type: EXPERIMENTAL
Intervention: Diet (N = 26)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Diet-Exercise (N = 28)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control (N = 27)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Exercise (N = 26)
Number of subjects: 107
Study: 26670970

Group type: EXPERIMENTAL
Intervention: HSCT (n=23)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (n=22)
Number of subjects: 45
Study: 23656645

Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (1 g daily)
Number of subjects: 12513

Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 12513
Study: 21245085

Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy (21-mg nicotine transdermal patch)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (placebo patch)
Number of subjects: 40
Study: 18291067

Group type: EXPERIMENTAL
Intervention: Visual Inspection with Acetic Acid and Magnification (VIAM)
Number of subjects: 358

Group type: COMPARATOR
Intervention: Visual Inspection with Acetic Acid (VIA)
Number of subjects: 358
Study: 16600927

Group type: EXPERIMENTAL
Intervention: Eucaloric low-fat, high-carbohydrate diet
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Ad libitum low-fat, high-carbohydrate diet
Number of subjects: 22
Study: 12741860

Group type: EXPERIMENTAL
Intervention: Amino Acid (AA)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 17
Study: 11001674

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus cisplatin (GC)
Number of subjects: 405

Group type: COMPARATOR
Intervention: Methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC)
Number of subjects: 405
Study: 8760987

Group type: EXPERIMENTAL
Intervention: Full angioscopic (ANG) vein preparation
Number of subjects: 47

Group type: COMPARATOR
Intervention: Conventional (CON) in situ grafting
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Completion angioscopy
Number of subjects: 47

Group type: COMPARATOR
Intervention: Arteriography
Number of subjects: 47
Study: 1314065

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH) CY 216, 48 mg subcutaneous injection and two placebo injections per day.
Number of subjects: 341

Group type: COMPARATOR
Intervention: Unfractionated heparin (UH), 5000 IU t.i.d.
Number of subjects: 341
Study: 3882058

Group type: EXPERIMENTAL
Intervention: Bezafibrate (10 to 20 mg/kg/day, twice daily)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Bezafibrate
Number of subjects: 14
Study: 31910891

Group type: EXPERIMENTAL
Intervention: Enriched GLB (McGill CHIP Healthy Weight Program)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Standard GLB
Number of subjects: 110
Study: 31572293

Group type: EXPERIMENTAL
Intervention: Intravenous alteplase
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 28420324

Group type: EXPERIMENTAL
Intervention: ICT-enhanced integrated care model (SPEC)
Number of subjects: 10
Study: 25299401

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 56

Group type: COMPARATOR
Intervention: Nebivolol
Number of subjects: 56
Study: 24571216

Group type: EXPERIMENTAL
Intervention: Responsive stimulation intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enhanced nutrition intervention
Number of subjects: 0
Study: 22512843

Group type: EXPERIMENTAL
Intervention: Gefitinib (250 mg per day orally)
Number of subjects: 296

Group type: COMPARATOR
Intervention: Placebo (orally)
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 296

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 296
Study: 18635285

Group type: EXPERIMENTAL
Intervention: gemcitabine/oxaliplatin/vinorelbine combination
Number of subjects: 39
Study: 16814221

Group type: EXPERIMENTAL
Intervention: CenteringPregnancy
Number of subjects: 98

Group type: COMPARATOR
Intervention: Traditional prenatal care
Number of subjects: 98
Study: 14522634

Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.1% and 0.03% ointment
Number of subjects: 16000

Group type: EXPERIMENTAL
Intervention: Tacrolimus ointment
Number of subjects: 16000
Study: 10979901

Group type: EXPERIMENTAL
Intervention: rhIL-12 (3-300 ng/kg)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: rhIL-12 (1000 ng/kg)
Number of subjects: 47
Study: 8761839

Group type: EXPERIMENTAL
Intervention: Exercise (5 days per week of supervised treadmill exercise plus stair climbing for 12 weeks)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (no exercise for 12 weeks)
Number of subjects: 22
Study: 1564133

Group type: EXPERIMENTAL
Intervention: Medication vial with a digital timepiece cap (Phase I)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard medication vial (Phase I control)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Timepiece cap and pocket-size card (Phase II)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Timepiece cap, pocket-size card, and blood pressure cuff (Phase II)
Number of subjects: 70
Study: 3907314

Group type: EXPERIMENTAL
Intervention: Moricizine (ethmozine) 10 to 12 mg/kg/day, administered every 12 hours
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Moricizine (ethmozine) 10 to 12 mg/kg/day, administered every 8 hours
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Moricizine (ethmozine) every 12 hours
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Moricizine (ethmozine) every 8 hours
Number of subjects: 10
Study: 31738682

Group type: EXPERIMENTAL
Intervention: Self-directed active learning (SDL)
Number of subjects: 100

Group type: COMPARATOR
Intervention: In-person instructor demonstration
Number of subjects: 100

Group type: COMPARATOR
Intervention: Online module instruction
Number of subjects: 100
Study: 30806952

Group type: EXPERIMENTAL
Intervention: Music intervention (Symphony No. 40 by Mozart played via headphones) during dental care
Number of subjects: 34

Group type: COMPARATOR
Intervention: No music intervention
Number of subjects: 34
Study: 29949175

Group type: EXPERIMENTAL
Intervention: SGLT‐2 inhibitor in addition to routine insulin therapy
Number of subjects: 126

Group type: COMPARATOR
Intervention: Insulin therapy only
Number of subjects: 126
Study: 26038610

Group type: EXPERIMENTAL
Intervention: Visual cues combined with treadmill training
Number of subjects: 23

Group type: COMPARATOR
Intervention: Pure treadmill training
Number of subjects: 23
Study: 24635550

Group type: EXPERIMENTAL
Intervention: Cocaine abstinence during treatment (8 or 12 weeks)
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: Cocaine use measures (percent days abstinent, percent positive urines, maximum days of consecutive abstinence)
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: Dichotomous measure of cocaine use (≥21 consecutive days of abstinence)
Number of subjects: 434
Study: 22452356

Group type: EXPERIMENTAL
Intervention: Olaparib (400 mg twice daily)
Number of subjects: 265

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Olaparib
Number of subjects: 265
Study: 20472995

Group type: EXPERIMENTAL
Intervention: PMMA‐CHDF (continuous hemodiafiltration with a cytokine‐adsorbing hemofilter)
Number of subjects: 51

Group type: COMPARATOR
Intervention: IHD+CHF (intermittent hemodialysis without water removal for elimination of metabolites and continuous hemofiltration for fluid management)
Number of subjects: 51
Study: 18095008

Group type: EXPERIMENTAL
Intervention: Hydromorphone (HM)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Morphine (M)
Number of subjects: 100
Study: 15990269

Group type: EXPERIMENTAL
Intervention: Experimental group (received clustering strategies)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (received original instructions only)
Number of subjects: 120
Study: 12480803

Group type: EXPERIMENTAL
Intervention: CHF with palm olein (PO)
Number of subjects: 22

Group type: COMPARATOR
Intervention: CHF without palm olein (PO)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: SPF with palm olein (PO)
Number of subjects: 22

Group type: COMPARATOR
Intervention: SPF without palm olein (PO)
Number of subjects: 22
Study: 10780808

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg) + Ethanol (0.5 g/kg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Naltrexone (100 mg) + Ethanol (1.0 g/kg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg) + Pentobarbital (150 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Naltrexone (100 mg) + Pentobarbital (300 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Ethanol (0 g/kg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Pentobarbital (0 mg)
Number of subjects: 16
Study: 7862544

Group type: EXPERIMENTAL
Intervention: Motor Performance Inventory (MPI)
Number of subjects: 197
Study: 1719716

Group type: EXPERIMENTAL
Intervention: Modified cholera chemical vaccine (choleragen‐toxoid + O‐antigens Inaba and Ogawa)
Number of subjects: 278

Group type: COMPARATOR
Intervention: Commercial batch of monovalent cholera vaccine (choleragen‐toxoid + O‐antigen Inaba)
Number of subjects: 278
Study: 6110954

Group type: EXPERIMENTAL
Intervention: bendroflumethiazide
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: propranolol
Number of subjects: 53
Study: 31425383

Group type: EXPERIMENTAL
Intervention: Sprint Interval Training (SIT)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 26